Samchundang Pharmaceutics Turns to Operating Profit in Q1 on Eylea Biosimilar Growth
Eylea Biosimilar Records 3.8 Billion Won in Quarterly Operating Profit
Samchundang Pharmaceutics announced on the 18th that, on a standalone basis, it recorded sales of 45.5 billion won and operating profit of 2.4 billion won in the first quarter of this year. Compared to the same period last year, sales increased by 25.0%, and operating profit turned to the black from an operating loss of 300 million won in the first quarter of last year.
The Eylea biosimilar business posted sales of 10.5 billion won and operating profit of 3.8 billion won in the first quarter. This is similar to the fourth quarter of last year, when it recorded sales of 10.7 billion won and operating profit of 4.7 billion won.
The company explained that the first quarter results reflected the impact of overseas contract manufacturing organization (CMO) facility inspections and logistics disruptions. Production was halted from mid-February to the end of March due to a regular GMP inspection of the CMO. In addition, the company explained that export volumes to Europe temporarily decreased due to logistics disruptions stemming from the conflict between Iran and the United States. The company stated that export volumes will be sequentially reflected from the second quarter as supply schedules normalize.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An official from Samchundang Pharmaceutics said, "After the launch in Europe at the end of November last year, profit-sharing revenue was initially limited, but as local prescriptions expand, related revenues are expected to increase."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.